Literature DB >> 22449784

Rational design of vaccines: learning from immune evasion mechanisms of persistent viruses and tumors.

Ramon Arens1.   

Abstract

The induction of adaptive immunity and prevention of tolerance is a critical component of vaccination and immunotherapy in order to prevent pathogen-related diseases and to eradicate malignant cells. Although many acute infections can be controlled by vaccination, the development of prophylactic and therapeutic vaccines against persistent viruses and tumors remains challenging. The diverse immune evasion strategies used by persistent DNA viruses such as herpesviruses contribute directly to their persistence and escape from immune control. Intriguingly, many tumors have also developed escape mechanisms to dismantle similar aspects of the host's immune system. Analogous targets of immune evasion mechanisms comprise suppression of antigen presentation and T cell costimulatory pathways, induction of immunosuppressive cytokines, and obstruction of interferon and chemokine functions, which emphasizes them not only as critical elements of T cell activation pathways but also as the potential "Achilles' heels" of the host immune system. The insight that immune evasion by viruses and tumors targets analogous host immune pathways might lead to cross-pollination of the viral and tumor immunology research fields, which could lead to new perspectives and appreciation of the intricacies and subtleties that arise from the merging of these fields. Accordingly, a rational and combinatorial manipulation of immune evasion pathways and their targets should aid in the development of safer and more effective vaccine strategies and immunotherapies for a wide range of infections and malignancies.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22449784     DOI: 10.1016/B978-0-12-396548-6.00009-3

Source DB:  PubMed          Journal:  Adv Immunol        ISSN: 0065-2776            Impact factor:   3.543


  10 in total

Review 1.  True grit: programmed necrosis in antiviral host defense, inflammation, and immunogenicity.

Authors:  Edward S Mocarski; William J Kaiser; Devon Livingston-Rosanoff; Jason W Upton; Lisa P Daley-Bauer
Journal:  J Immunol       Date:  2014-03-01       Impact factor: 5.422

2.  Evaluation of humoral and cellular immune responses to a DNA vaccine encoding chicken type II collagen for rheumatoid arthritis in normal rats.

Authors:  Zhao Xiao; Long Juan; Yun Song; Zhang Zhijian; Jin Jing; Yu Kun; Hao Yuna; Dai Dongfa; Ding Lili; Tan Liuxin; Liang Fei; Liu Nan; Yuan Fang; Sun Yuying; Xi Yongzhi
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Enhanced cross-presentation and improved CD8+ T cell responses after mannosylation of synthetic long peptides in mice.

Authors:  Judith Rauen; Christoph Kreer; Arlette Paillard; Suzanne van Duikeren; Willemien E Benckhuijsen; Marcel G Camps; A Rob P M Valentijn; Ferry Ossendorp; Jan W Drijfhout; Ramon Arens; Sven Burgdorf
Journal:  PLoS One       Date:  2014-08-19       Impact factor: 3.240

4.  HHV-6A/6B Infection of NK Cells Modulates the Expression of miRNAs and Transcription Factors Potentially Associated to Impaired NK Activity.

Authors:  Roberta Rizzo; Irene Soffritti; Maria D'Accolti; Daria Bortolotti; Dario Di Luca; Elisabetta Caselli
Journal:  Front Microbiol       Date:  2017-10-31       Impact factor: 5.640

5.  Human Herpesvirus 6A and 6B inhibit in vitro angiogenesis by induction of Human Leukocyte Antigen G.

Authors:  Roberta Rizzo; Maria D'Accolti; Daria Bortolotti; Francesca Caccuri; Arnaldo Caruso; Dario Di Luca; Elisabetta Caselli
Journal:  Sci Rep       Date:  2018-12-06       Impact factor: 4.379

Review 6.  Treatment of Metastatic Disease through Natural Killer Cell Modulation by Infected Cell Vaccines.

Authors:  Seyedeh Raheleh Niavarani; Christine Lawson; Lee-Hwa Tai
Journal:  Viruses       Date:  2019-05-11       Impact factor: 5.048

Review 7.  Current view on novel vaccine technologies to combat human infectious diseases.

Authors:  Zrinka Matić; Maja Šantak
Journal:  Appl Microbiol Biotechnol       Date:  2021-12-10       Impact factor: 4.813

8.  Predicting the efficacy of cancer vaccines by evaluating T-cell responses.

Authors:  Suzanne van Duikeren; Ramon Arens
Journal:  Oncoimmunology       Date:  2013-01-01       Impact factor: 8.110

Review 9.  Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer.

Authors:  Sara A Collins; Ashish H Shah; Derek Ostertag; Noriyuki Kasahara; Douglas J Jolly
Journal:  Expert Opin Biol Ther       Date:  2021-05-06       Impact factor: 5.589

Review 10.  Cytomegalovirus infection and progressive differentiation of effector-memory T cells.

Authors:  Iris N Pardieck; Guillaume Beyrend; Anke Redeker; Ramon Arens
Journal:  F1000Res       Date:  2018-09-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.